• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Nordson Corporation Appoints Milton Morris to Board of Directors

    9/15/22 4:30:00 PM ET
    $BSX
    $EMBC
    $MYO
    $NDSN
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BSX alert in real time by email

    Nordson Corporation (NASDAQ:NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors. Dr. Morris will bring robust business leadership experience, as well as a legacy of successful product innovation, to the board.

    "We are pleased to welcome Milton as a new independent director. His passion for innovation and new product development aligns well with Nordson's strength of understanding customer needs and bringing diversified precision technology solutions to market. In addition, his professional background in medical devices will enhance our understanding, as Nordson plans to further expand acquisitively in this exciting space. We look forward to bringing Milton's perspective to the board," said Michael Merriman, chair of the board of directors, Nordson Corporation.

    Throughout his career, Dr. Morris has demonstrated a passion for product development that improves people's lives. He has also led decentralized organizations, growing successful businesses and cultivating diverse and inclusive talent pipelines.

    "I look forward to partnering with the Nordson board of directors and executive management team. The company is making solid progress on its Ascend strategy to achieve top tier growth with leading margins and returns. I am excited to reinforce their strong commitment to innovation while also sharing my unique perspective from the medical device industry," said Dr. Morris.

    Dr. Morris's appointment brings the number of Nordson directors to nine, following the departure earlier this year of Arthur George, who served on Nordson's board for ten years. Dr. Morris will serve on the board's audit committee immediately upon appointment.

    About Milton Morris

    Dr. Morris retired in 2022 from Neuspera Medical Inc., a privately held, venture-backed, clinical stage neuromodulation company committed to developing implantable medical device technology focused on improving the lives of patients battling chronic illness or dysfunction. He served as president and chief executive officer of Neuspera since 2015. Dr. Morris currently serves as a Principal of MEHL BioMedical, LLC, where he has provided consulting services to start-up companies in the biomedical device industry since 2015. He previously was the senior vice president, research and development of Cyberonics, Inc., maker of the Vagus Nerve Stimulation (VNS Therapy) System from 2009 through 2014. His prior work experience also includes serving as a director, program management and operations of InnerPulse, Inc., a developer of technology, devices, software protocols, and procedures to transform the treatment of cardiac arrhythmias, as well as director, marketing and arrhythmia franchise leader of Boston Scientific Corporation (NYSE:BSX), a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties. He serves as a director on the boards of Embecta Corp. (NASDAQ:EMBC) and Myomo, Inc. (NYSE:MYO).

    Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company's direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at www.nordson.com, www.twitter.com/Nordson_Corp or www.facebook.com/nordson.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220915006087/en/

    Get the next $BSX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BSX
    $EMBC
    $MYO
    $NDSN

    CompanyDatePrice TargetRatingAnalyst
    Nordson Corporation
    $NDSN
    6/18/2025Peer Perform
    Wolfe Research
    Nordson Corporation
    $NDSN
    6/17/2025$245.00Hold
    Vertical Research
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Nordson Corporation
    $NDSN
    5/30/2025$260.00Perform → Outperform
    Oppenheimer
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    Embecta Corp.
    $EMBC
    4/10/2025$15.00Neutral
    Mizuho
    Nordson Corporation
    $NDSN
    3/4/2025$260.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Nordson Corporation
    $NDSN
    2/24/2025$219.00Outperform → Neutral
    Exane BNP Paribas
    More analyst ratings

    $BSX
    $EMBC
    $MYO
    $NDSN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      5/23/25 4:35:56 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Kirk Thomas F bought $125,993 worth of shares (38,767 units at $3.25), increasing direct ownership by 13% to 344,700 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/15/25 4:53:28 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Chief Executive Officer Gudonis Paul R bought $96,612 worth of shares (30,000 units at $3.22), increasing direct ownership by 3% to 1,051,671 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/15/25 4:36:08 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $BSX
    $EMBC
    $MYO
    $NDSN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 1, 2024 - FDA Roundup: March 1, 2024

      For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

      3/1/24 4:00:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $EMBC
    $MYO
    $NDSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Nordson

      Wolfe Research initiated coverage of Nordson with a rating of Peer Perform

      6/18/25 7:58:36 AM ET
      $NDSN
      Industrial Machinery/Components
      Industrials
    • Vertical Research initiated coverage on Nordson with a new price target

      Vertical Research initiated coverage of Nordson with a rating of Hold and set a new price target of $245.00

      6/17/25 8:09:40 AM ET
      $NDSN
      Industrial Machinery/Components
      Industrials
    • Leerink Partners initiated coverage on Boston Scientific with a new price target

      Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

      6/16/25 7:46:14 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $EMBC
    $MYO
    $NDSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ludwig Edward J sold $424,120 worth of shares (4,000 units at $106.03), decreasing direct ownership by 18% to 18,479 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/28/25 4:10:19 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • New insider Rutledge Joseph M claimed no ownership of stock in the company (SEC Form 3)

      3 - NORDSON CORP (0000072331) (Issuer)

      7/24/25 1:46:11 PM ET
      $NDSN
      Industrial Machinery/Components
      Industrials
    • VP and CAO Shamrock Stephen F disposed of $262,894 worth of NDSN (1,178 units at $223.17), decreasing direct ownership by 75% to 391 units (SEC Form 4)

      4 - NORDSON CORP (0000072331) (Issuer)

      7/14/25 4:50:49 PM ET
      $NDSN
      Industrial Machinery/Components
      Industrials

    $BSX
    $EMBC
    $MYO
    $NDSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • embecta to Report Fiscal Third Quarter 2025 Financial Results

      PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, August 8, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00

      7/24/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces results for second quarter 2025

      MARLBOROUGH, Mass., July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported basis, 21.6 percent on an operational1 basis and 17.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.62 a year ago.

      7/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

      The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of drug refractory, symptomatic persistent atrial fibrillation (AF), an arrythmia in which the heart beats abnormally for at least seven days.

      7/7/25 7:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $EMBC
    $MYO
    $NDSN
    SEC Filings

    See more
    • Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      7/23/25 6:32:54 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NORDSON CORP (0000072331) (Filer)

      7/14/25 8:33:56 AM ET
      $NDSN
      Industrial Machinery/Components
      Industrials
    • SEC Form 144 filed by Myomo Inc.

      144 - MYOMO, INC. (0001369290) (Subject)

      6/30/25 8:12:58 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $BSX
    $EMBC
    $MYO
    $NDSN
    Leadership Updates

    Live Leadership Updates

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Medical and Fluid Solutions Segment Leadership Transition

      Nordson Corporation (NASDAQ:NDSN) announced today that Justin Hall has been promoted to Executive Vice President (EVP) and Medical and Fluid Solutions (MFS) segment leader. Mr. Hall joined Nordson in 2006 and has a strong performance track record. He has held leadership positions within the Company's three segments and built deep expertise in deploying the NBS Next growth framework. Stephen Lovass, former EVP and MFS segment leader, will be leaving the Company, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428677805/en/Justin Hall "Justin is a tenured Nordson leader who has deployed NBS Next holisticall

      4/28/25 4:30:00 PM ET
      $NDSN
      Industrial Machinery/Components
      Industrials
    • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

      Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

      4/3/25 11:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care

    $BSX
    $EMBC
    $MYO
    $NDSN
    Financials

    Live finance-specific insights

    See more
    • embecta to Report Fiscal Third Quarter 2025 Financial Results

      PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, August 8, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00

      7/24/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces results for second quarter 2025

      MARLBOROUGH, Mass., July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported basis, 21.6 percent on an operational1 basis and 17.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.62 a year ago.

      7/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $EMBC
    $MYO
    $NDSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/8/24 10:57:43 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/7/24 4:21:15 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Embecta Corp.

      SC 13G - Embecta Corp. (0001872789) (Subject)

      10/25/24 5:45:30 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care